Skip to main content

Advertisement

SpringerLink
Log in

Treatment of IgA nephropathy with renal insufficiency

  • Review
  • Published:
Journal of Nephrology Aims and scope Submit manuscript

Abstract

IgA Nephropathy leads young people to dialysis more often than other glomerular diseases, because often diagnosis and therapy are made late. Nephrologists waive to treat IgAN pts with chronic renal insufficiency, believing that treatment may not be effective and safe. Moreover, studies in IgAN pts with reduced renal function are lacking. Small studies seem to indicate a possible utility of RAS blockers and corticosteroids in these patients. Recently, VALIGA study showed that corticosteroids and immunosuppressants were more frequently used in pts with eGFR <30 ml/min than in those with eGFR >30 ml/min (60 vs. 44 %, respectively; p = 0.004). The goal of treating IgAN pts is to obtain a time-average proteinuria <1 g/day, regardless of the degree of renal function and histological damage. RASB and corticosteroids seem to be able to obtain this result. However, it’s important to pay attention to the appearance of adverse events of CS. In the literature, major side effects occurred in 29 of 463 (6.2 %) patients enrolled in RCTs. However, scarce informations are obtained about the safety of CS in patients with reduced renal function. To better evaluate this aspect, we considered three studies, that used similar schemes of therapy and included patients with different degrees of renal function (1: GFR 90 ml/min/1.73 m2, 2: 81 ml/min/1.73 m2, 3: 34 ml/min/1.73 m2). The occurrence of adverse events increased with the worsening of renal function (2.3, 5.7 and 15.4 % in studies 1, 2 and 3 respectively). The aim of the treatment for a patient with an eGFR <30 is to slow the progression and to delay the need for dialysis. Therefore, in stage CKD 2, 3 and 4 with a proteinuria >1 g/day a 6-month course of corticosteroids could be useful and safe.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Italian Registry of Dialysis and Transplantation (2010) www.sin-italy.org

  2. Floege J, Johnson RJ, Feehally J (2011) Comprehensive clinical nephrology. In: Section IV: Glomerular disease, 4th edn, vol 1. Elsevier, pp 218–282

  3. KDIGO (2012) Clinical practice guidelines for glomerulonephritis—chapter 10: immunoglobulin A nephropathy. Kidney Int Suppl 2: S209–S217

  4. Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, Kirschstein M, Linné T (2007) IgACE: a placebocontrolled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgAN and moderate proteinuria. J Am Soc Nephrol 18:1880–1888

    Article  CAS  PubMed  Google Scholar 

  5. Li PKT, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC (2006) Hong Kong study using Valsartan in IgAN (HKVIN)—A double-blind randomized placebo-controlled study. Am J Kidney Dis 47:751–760

    Article  CAS  PubMed  Google Scholar 

  6. Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E (2003) Treatment of IgAN with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 14:1578–1583

    Article  CAS  PubMed  Google Scholar 

  7. Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, Roberts IS, Morando L, Camilla R, Tesar V, Lunberg S, Gesualdo L, Emma F, Rollino C, Amore A, Praga M, Feriozzi S, Segoloni G, Pani A, Cancarini G, Durlik M, Moggia E, Mazzucco G, Giannakakis C, Honsova E, Sundelin BB, Di Palma AM, Ferrario F, Gutierrez E, Asunis AM, Barratt J, Tardanico R, Perkowska-Ptasinska A, VALIGA study of the ERA-EDTA Immunonephrology Working Group (2014) Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int 86(4):828–836

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ruggenenti P, Perna A, Remuzzi G (2001) ACE inhibitors to prevent end-stage renal disease when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril efficacy in nephropathy. J Am Soc Nephrol 12:2832–2837

    CAS  PubMed  Google Scholar 

  9. Ruggenenti P, Perna A, Benini R, Bertani T, Zoccali C, Maggiore Q, Salvadori M, Remuzzi G (1999) In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of GISEN Group. J Am Soc Nephrol 10:997–1006

    CAS  PubMed  Google Scholar 

  10. Glassock RJ, Winearls C (2009) Ageing and the glomerular filtration rate truths and consequences. Trans Am Clin Climatol Assoc 120:419–428

    PubMed  PubMed Central  Google Scholar 

  11. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW (2006) Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 354:131–140

    Article  CAS  PubMed  Google Scholar 

  12. Van der Meer IM, Cravedi P, Remuzzi G (2010) The role of renin angiotensin system inhibition in kidney repair. Fibrogenesis Tissue Repair 3:7

    Article  PubMed  PubMed Central  Google Scholar 

  13. The GISEN Group (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric non-diabetic nephropathy. Lancet 349:1857–1863

    Article  Google Scholar 

  14. Casas JP, Chua W, Loukogeorgakis S et al (2005) Effects of inhibitors of the rennin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366:2026–2033

    Article  CAS  PubMed  Google Scholar 

  15. Manno C, Torres DD, Rossini M, Pesce F, Schena FP (2009) Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 24(12):3694–3701

    Article  CAS  PubMed  Google Scholar 

  16. Lv J, Zhang H, Chen Y et al (2009) Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 53(1):26–32

    Article  CAS  PubMed  Google Scholar 

  17. Tamura S, Ueki K, Ideura H, Tsukada Y, Maezawa A, Kawai H, Wakamatsu R, Yano S, Nojima Y, Naruse T (2001) Corticosteroid therapy in patients with IgA nephropathy and impaired renal function. Clin Nephrol 55:192–195

    CAS  PubMed  Google Scholar 

  18. Suzuki S, Joh K (2004) Applicability of steroid therapy in 275 adult patients with IgA nephropathy determined using a histological scoring system and degree of proteinuria. Clin Exp Nephrol 8:109–116

    PubMed  Google Scholar 

  19. Moriyama T, Honda K, Nitta K, Yumura W, Nihei H (2004) The effectiveness of steroid therapy for patients with advanced IgA nephropathy and impaired renal function. Clin Exp Nephrol 8:237–242

    Article  CAS  PubMed  Google Scholar 

  20. Ballardie FW, Roberts IF (2002) Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 13:142–148

    CAS  PubMed  Google Scholar 

  21. Pozzi C, Andrulli S, Pani A, Scaini P, Roccatello D, Fogazzi GB, Pecchini P, Rustichelli R, Finocchiaro P, Del Vecchio L, Locatelli F (2013) IgA nephropathy with severe chronic renal failure: a randomized controlled trial with corticosteroids and azathioprine. J Nephrol 26:86–93

    Article  CAS  PubMed  Google Scholar 

  22. D’Amico G, Ragni A, Gandini E, Fellin G (1993) Typical and atypical natural history of IgA nephropathy in adult patients. Contrib Nephrol 104:6–13

    Article  PubMed  Google Scholar 

  23. Schöll U, Wastl U, Risler T et al (1999) The “point of no return” and the rate of progression in the natural history of IgA nephritis. Clin Nephrol 52(5):285–292

    PubMed  Google Scholar 

  24. A Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D’Agati V, D’Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Leung CB, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76:534–545

    Article  Google Scholar 

  25. Yoshikawa N, For the Japanese Pediatric IgA Nephropathy Study Group (1999) A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. J Am Soc Nephrol 10:101–109

    CAS  PubMed  Google Scholar 

  26. Shoji T, Nakanishi I, Suzuki A, Hayashi T, Togawa M, Okada N, Imai E, Hori M, Tsubakihara Y (2000) Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephopathy. Am J Kidney Dis 2:194–201

    Article  Google Scholar 

  27. Hotta O, Furuta T, Chiba S, Tomioka S, Taguma Y (2002) Regression of IgA nephropathy: a repeat biopsy study. Am J Kidney Dis 39:493–502

    Article  PubMed  Google Scholar 

  28. Pozzi C, Ferrario F, Visciano B, Del Vecchio L (2012) Corticosteroids in patients with IgA nephropathy and severe chronic renal damage. Case Rep Nephrol 2012:180691. doi:10.1155/2012/180691

    PubMed  PubMed Central  Google Scholar 

  29. Tesar V, Troyanov S, Bellur S, Verhave JC, Cook HT, Feehally J, Roberts ISD, Cattran D, Coppo R, On behalf of the VALIGA study of ERA-EDTA Immunonephrology Working Group (2015) Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study. J Am Soc Nephrol 26(9):2248–2258

    Article  CAS  PubMed  Google Scholar 

  30. Alamartine E, Sabatier JC, Guerin C, Berliet JM, Bertoux F (1991) Prognostic factor in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analysis. Am J Kidney Dis 18:12–19

    Article  CAS  PubMed  Google Scholar 

  31. Radford MG, Donadio JV, Bergstralh EJ, Grande JP (1997) Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 8:192–207

    Google Scholar 

  32. D’Amico G (2000) Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis 36:227–237

    Article  PubMed  Google Scholar 

  33. Reich HN, Troyanov S, Scholey JW, Cattran D, For the Toronto Glomerulonephritis Registry (2007) Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 18:3177–3183

    Article  CAS  PubMed  Google Scholar 

  34. Sarcina C, Tinelli C, Ferrario F, Pani A, De Silvestri A, Scaini P, Del Vecchio L, Alberghini E, Buzzi L, Baragetti I, Pozzi C (2015) Changes in proteinuria and side effects of corticosteroids alone or in combination with azathioprine at different stages of IgA Nephropathy. Clin J Am Soc Nephrol (accepted)

  35. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, Locatelli F (1999) Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353(9156):883–887

    Article  CAS  PubMed  Google Scholar 

  36. Pozzi C, Andrulli S, Pani A, Scaini P, Del Vecchio L, Fogazzi G, Vogt B, De Cristofaro V, Allegri L, Cirami L, Procaccini AD, Locatelli F (2010) Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 21(10):1783–1790

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Sarcina C, Tinelli C, Ferrario F, Visciano B, Terraneo V, Pani A, Fogazzi GB, Furiani S, Alberghini E, Buzzi L, Pozzi C (2012) What are the most important prognostic factors for renal survival in IgA nephropathy? Nephrol Dial Transplant 27(Suppl 2):F0013

    Google Scholar 

  38. Ponticelli C, Glassock RJ (1997) Glucocorticoid and immunomodulating agents. In: Treatment of primary glomerulonephritis, Oxford Clinical Nephrology Series. Oxford University Press, Oxford, pp 31–33

    Google Scholar 

  39. Lai KN, Lai FM, Ho CP, Chan KW (1986) Corticosteroid therapy in IgA nephropathy with nephritic syndrome: a long-term controlled trial. Clin Nephrol 26:174–180

    CAS  PubMed  Google Scholar 

  40. Julian BA, Barker C (1993) Alternate-day prednisone therapy in IgA nephropathy. Contrib Nephrol 104:198–206

    Article  CAS  PubMed  Google Scholar 

  41. Katafuchi R, Iheda K, Mizumasa T, Tanaka H, Ando T, Yanase T, Masutani K, Kubo M, Fujimi S (2003) Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am J Kidney Dis 41:972–983

    Article  CAS  PubMed  Google Scholar 

  42. Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, Ito H, For the Japanese Pediatric IgA Nephropathy Treatment Studi Group (2006) Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol 1:511–517

    Article  CAS  PubMed  Google Scholar 

  43. Koike M, Takei T, Uchida K, Honda K, Moriyama T, Horita S, Ogawa T, Yoshida T, Tsuchiya K, Nitta K (2008) Clinical assessment of low-dose steroid therapy for patients with IgA nephropathy: a prospective study in a single center. Clin Exp Nephrol 12:250–255

    Article  CAS  PubMed  Google Scholar 

  44. Kobayashi Y, Hiki Y, Kokubo T, Horii A, Tateno S (1996) Steroid therapy during the early stage of progressive IgA Nephropathy. Nephron 72:237–242

    Article  CAS  PubMed  Google Scholar 

  45. Kanno Y, Witt M, Okada H, Nemoto H, Sugahara S, Nakamoto H et al (2003) A comparison of corticosteroid and warfarin therapy in IgA nephropathy with crescent formation: preliminary trial. Clin Exp Nephrol 7(1):48–51

    Article  CAS  PubMed  Google Scholar 

  46. Hogg RJ, Lee J, Nardelli N, Julian BA, Cattran D, Waldo B, Wyatt R, Jennette C, Sibley R, Hyland K, Fitzgibbons L, Hirschman G, Donadio Jv, Holub BJ (2006) Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy; report from the southwest pediatric nephrology studi group. Clin J Am Soc Nephrol 1:467–474

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nephrology and Dialysis Department, Bassini Hospital, Cinisello Balsamo, Italy

    Claudio Pozzi, Cristina Sarcina & Francesca Ferrario

Authors
  1. Claudio Pozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cristina Sarcina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesca Ferrario
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claudio Pozzi.

Ethics declarations

Conflict of interest

None.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pozzi, C., Sarcina, C. & Ferrario, F. Treatment of IgA nephropathy with renal insufficiency. J Nephrol 29, 551–558 (2016). https://doi.org/10.1007/s40620-015-0257-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40620-015-0257-2

Keywords

Search

Navigation